Verrica Pharmaceuticals Inc. (VRCA)
$5.25
$-0.11
(-2.05%)
As on 04-Sep-2026 13:18EDT
Market cap
$98 Mln
Revenue (TTM)
$30 Mln
P/E Ratio
--
P/B Ratio
20.6
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-2.4 %
-
ROCE
-- %
-
Industry P/E
37.32
-
EV/EBITDA
-11.7
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1.9
-
Face value
--
-
Shares outstanding
17,178,786
8 Years Aggregate
CFO
$-166.49 Mln
EBITDA
$-210.55 Mln
Net Profit
$-234.04 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Verrica Pharmaceuticals (VRCA)
| -36.8 | 0.0 | -10.6 | 0.4 | -51.6 | -48.1 | -- |
|
BSE Sensex
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Verrica Pharmaceuticals (VRCA)
| 18.7 | -90.3 | 166.2 | -70.0 | -20.4 | -27.6 | 95.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Verrica Pharmaceuticals (VRCA)
|
5.3 | 97.8 | 30.3 | -31.2 | -90.5 | -214.7 | -- | 20.6 |
| 17.4 | 6,074.3 | 3,117.6 | 157.4 | 14.7 | -- | 36.3 | 186.5 | |
| 206.5 | 10,424.8 | 776.6 | -191.6 | -17.6 | -223.4 | -- | 129.6 | |
| 74.2 | 14,974.8 | 691.8 | -696.2 | -89.1 | -- | -- | 123.7 | |
| 111.2 | 12,310.3 | 830.8 | 54.9 | 3.2 | 8.1 | 264.8 | 17.9 | |
| 12.0 | 10,020.9 | 332,834.2 | 33,166.6 | 11.1 | 8.9 | 29.3 | 2.5 | |
| 24.4 | 12,236.5 | 5,020.0 | -199.0 | 1.6 | -3 | -- | 1.9 | |
| 287.5 | 5,591.7 | 290.5 | 197.2 | 82.5 | 19.9 | 28.9 | 5.9 | |
| 68.4 | 6,058.9 | 450.9 | 138.6 | 39.1 | 115.6 | 50.1 | 32.1 | |
| 124.7 | 8,865.6 | 431.8 | -136.7 | -30.8 | -30.3 | -- | 21.5 |
Shareholding Pattern
View DetailsAbout Verrica Pharmaceuticals (VRCA)
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device... combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania. Read more
-
President, CEO & Director
Mr. Ted White
-
President, CEO & Director
Mr. Ted White
-
Headquarters
West Chester, PA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Verrica Pharmaceuticals (VRCA)
What is the current share price of Verrica Pharmaceuticals Inc (VRCA) Today?
The share price of Verrica Pharmaceuticals Inc (VRCA) is $5.25 (NASDAQ) as of 04-Sep-2026 13:18 EDT. Verrica Pharmaceuticals Inc (VRCA) has given a return of -51.6% in the last 3 years.
What is the current PB & PE ratio of Verrica Pharmaceuticals Inc (VRCA)?
Since, TTM earnings of Verrica Pharmaceuticals Inc (VRCA) is negative, P/E ratio is not available.
The P/B ratio of Verrica Pharmaceuticals Inc (VRCA) is 20.62 times as on 28-Aug-2026, a 166 premium to its peers’ median range of 7.75 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-4.95 |
3.58 |
2024 |
-0.06 |
-0.48 |
2023 |
-0.51 |
1.72 |
2022 |
-0.46 |
0.28 |
2021 |
-0.72 |
0.77 |
What is the 52 Week High and Low of Verrica Pharmaceuticals Inc (VRCA)?
The 52-week high and low of Verrica Pharmaceuticals Inc (VRCA) are Rs 9.82 and Rs 3.28 as of 05-Sep-2026.
What is the market cap of Verrica Pharmaceuticals Inc (VRCA)?
Verrica Pharmaceuticals Inc (VRCA) has a market capitalisation of $ 98 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Verrica Pharmaceuticals Inc (VRCA)?
Before investing in Verrica Pharmaceuticals Inc (VRCA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.